Rabeprazole is an antiulcer drug in the class of proton pump inhibitors. It is a prodrug - in the acid environment of the parietal cells it turns into active sulphenamide form. Rabeprazole inhibits the H+, K+ATPase of the coating gastric cells and dose-dependent oppresses basal and stimulated gastric acid secretion.
For the treatment of acid-reflux disorders (GERD), peptic ulcer disease, H. pylori eradication, and prevention of gastroinetestinal bleeds with NSAID use.
Clinical Pharmacology of Miami, Miami, Florida, United States
Alliance for Multispecialty Research, LLC, Knoxville, Tennessee, United States
Research Site, Cluj Napoca, Romania
Local Institution - 0001, Lenexa, Kansas, United States
The First Hospital of Jilin University, Changchun, Jilin, China
PPD Development, LP, Austin, Texas, United States
Pfizer Clinical Research Unit - Brussels, Brussels, Bruxelles-capitale, Région DE, Belgium
The First Hospital of Jilin University, Chang chun, Jilin, China
The First Hospital of Jilin University, Chang chun, Jilin, China
Parexel International, Baltimore, Maryland, United States
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.